**Directions given under the Human Tissue Act 2004, the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (As amended) (SI 2007 No.1523) and the Quality and Safety of Organs Intended for Transplantation Regulations 2012 (SI 2012 No.1501)**

|  |  |
| --- | --- |
| **Directions on licence fee structure for the financial year 2024/25** | Ref 001/2024 |
| **These Directions are** | Statutory Directions |

|  |  |
| --- | --- |
| **Section of the Human Tissue Act 2004, the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (SI 2007 No.1523) and the Quality and Safety of Organs Intended for Transplantation Regulations 2012 (SI 2012 No.1501) providing for these Directions** | Schedule 3, paragraph 2(4)(f) of the Human Tissue Act 2004, Regulation 8 of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 and Regulation 6 of the Quality and Safety of Organs Intended for Transplantation Regulations 2012 |
| **These Directions come into force on** | 2 April 2024 |
| **These Directions remain in force** | Until revoked |

1. These Directions revoke Directions 001/2023.
2. These Directions are made by the Human Tissue Authority under Schedule 3, paragraph 2(4)(f) of the Human Tissue Act 2004 and as applied by Regulation 8 of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended) and Regulation 6 of the Quality and Safety of Organs Intended for Transplantation Regulations 2012.
3. These Directions set out the licence fee structure of the Human Tissue Authority for the financial year commencing 1 April 2024.
4. Schedule 3, paragraph 2(4)(f) of the Human Tissue Act 2004, and as applied by Regulation 8 of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended) (SI 2007 No. 1523) and Regulation 6 of the Quality and Safety of Organs Intended for Transplantation Regulations 2012 (SI 2012 No.1501), provides that “it shall be a condition of a licence...that there shall be paid to the Authority at such times as may be specified in directions sums of such amount as may be so specified in respect of its costs in connection with superintending compliance with the terms of licences.”
5. The Human Tissue Authority licence fee structure:



Date 28 March 2024

Signed.............................................

Dr Colin Sullivan

**Chief Executive**

**Human Tissue Authority**